Valeant agrees $10 billion takeover of SalixLast year’s rumour of a Salix acquisition by Valeant proved well-founded, with the two companies announcing a $10 Share XValeant agrees $10 billion takeover of Salixhttps://pharmaphorum.com/news/valeant-agrees-10-billion-takeover-of-salix/
Sosei acquires UK biotech Heptares for $400 millionJapan’s Sosei has acquired biotech company Heptares in a deal which it says will create a major drug Share XSosei acquires UK biotech Heptares for $400 millionhttps://pharmaphorum.com/news/sosei-acquires-uk-biotech-heptares-for-400-million/
EU stakeholders form medicines traceability organisationA consortium of groups representing Europe’s drugmakers, wholesalers, pharmacists and parallel traders has formed a joint organisation to Share XEU stakeholders form medicines traceability organisationhttps://pharmaphorum.com/news/eu-stakeholders-form-medicines-traceability-organisation/
Olivier Brandicourt named as new Sanofi chief executiveAfter more than three months of searching, Sanofi has confirmed that Bayer’s Olivier Brandicourt is to be its Share XOlivier Brandicourt named as new Sanofi chief executivehttps://pharmaphorum.com/news/olivier-brandicourt-named-as-new-sanofi-chief-executive/
Eylea beats rivals in government-sponsored head-to-head trialResults from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer’s Eylea Share XEylea beats rivals in government-sponsored head-to-head trialhttps://pharmaphorum.com/news/eylea-beats-rivals-in-government-sponsored-head-to-head-trial/
Sanofi to develop novel autoimmune treatmentsSanofi has entered into a new collaboration with Netherlands-based biotech firm Lead Pharma, focused on developing novel treatments Share XSanofi to develop novel autoimmune treatmentshttps://pharmaphorum.com/news/sanofi-to-develop-novel-autoimmune-treatments/
Apple scales down health functions on smartwatchApple has reportedly had to rein in the health ambitions of its smartwatch because technological limitations mean it Share XApple scales down health functions on smartwatchhttps://pharmaphorum.com/news/apple-scales-down-health-functions-on-smartwatch/
Cost control urged for new PCSK9 cholesterol drugsPharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an Share XCost control urged for new PCSK9 cholesterol drugshttps://pharmaphorum.com/news/cost-control-urged-for-new-pcsk9-cholesterol-drugs/
Stivarga tipped to lead in China’s growing colorectal cancer marketA number of new treatments for colorectal cancer (CRC) are set to benefit from growing demand in China Share XStivarga tipped to lead in China’s growing colorectal cancer markethttps://pharmaphorum.com/news/stivarga-tipped-to-lead-in-china-s-growing-colorectal-cancer-market/
